Erasca Inc (ERAS)

$2.58 +0.04 (1.57%)
Market Cap 751.73M
Revenue (ttm) 0.00
Net Income (ttm) -161.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,491,600
Avg Vol 1,731,744
Day's Range N/A - N/A
Shares Out 283.67M
Stochastic %K 77%
Beta 1.19
Analysts Strong Sell
Price Target $3.86

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 465 6511
Address:
3115 Merryfield Row, Suite 300, San Diego, United States
JarvisFlow
JarvisFlow Nov. 14 at 2:19 PM
Guggenheim has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 3 → 5.
0 · Reply
Investor6
Investor6 Nov. 13 at 2:27 PM
$ERAS Erasca press release (ERAS): Q3 GAAP EPS of -$0.11 in-line. Cash, cash equivalents, and marketable securities were $362.4 million as of September 30, 2025, compared to $440.5 million as of December 31, 2024. Erasca expects its cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2028.
0 · Reply
RunnerSignals
RunnerSignals Nov. 12 at 9:23 PM
Market Warriors on the Move! $CNTA $TRX.X $ERAS $RANI $CHGG started down but closed strong
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Oct. 16 at 7:15 PM
$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS
2 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:44 PM
Stifel has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 4.
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 1:14 PM
Stifel initiates $ERAS coverage with Buy rating and $4.X target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition. https://notreload.xyz/erasca-gets-buy-rating-cancer-drug-potential/
0 · Reply
Quantumup
Quantumup Oct. 15 at 8:29 PM
Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.
0 · Reply
QuantInsider
QuantInsider Oct. 12 at 11:16 AM
What’s going on with $ERAS? Saw a big 7,072-contract ask-side sweep in those Jan 16 26 $2 calls on Oct 8 That’s about $842K at 172% IV Huge volume spike But with Morgan Stanley and BofA downgrades pushing it to a 2025 low, the risk is real Feels like early accumulation But I’m holding off Need to see if open interest grows next session and the call bid holds before thinking long Don’t jump the gun unless there’s follow-through in call OI and volume
0 · Reply
itoprag
itoprag Oct. 8 at 9:38 PM
$ERAS 15k shares, in at $1.29 on May 29, out today at $2.71. Not too shabby.
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 8 at 2:20 PM
👀 $ERAS Update 👀 Contracts are pushing close to 50% gains 💰
0 · Reply
Latest News on ERAS
Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Nov 12, 2025, 4:01 PM EST - 2 days ago

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Nov 6, 2025, 8:00 AM EST - 8 days ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Erasca to Present at Upcoming Conferences in November

Nov 4, 2025, 8:00 AM EST - 10 days ago

Erasca to Present at Upcoming Conferences in November

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 2 months ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Aug 12, 2025, 4:01 PM EDT - 3 months ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Erasca to Present at Upcoming Investor Conferences in June

May 29, 2025, 8:00 AM EDT - 6 months ago

Erasca to Present at Upcoming Investor Conferences in June

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 4:05 PM EDT - 6 months ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 13, 2025, 8:00 AM EDT - 6 months ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

Erasca to Present at the Bank of America Securities Health Care Conference

May 7, 2025, 8:00 AM EDT - 6 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Apr 29, 2025, 4:05 PM EDT - 7 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 7 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 8 months ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Mar 20, 2025, 4:01 PM EDT - 8 months ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 31, 2025, 8:00 AM EST - 10 months ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27, 2025, 12:09 AM EST - 10 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 21, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 16, 2024, 8:00 PM EDT - 1 year ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 8, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca to Present at the Bank of America Health Care Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Health Care Conference

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 29, 2024, 11:11 AM EDT - 1 year ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 8:30 PM EDT - 1 year ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Dec 11, 2023, 8:00 AM EST - 2 years ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 28, 2023, 8:00 AM EST - 2 years ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 9, 2023, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Erasca to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at Upcoming Investor Conferences in November

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Aug 28, 2023, 6:05 AM EDT - 2 years ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

Aug 14, 2023, 3:22 PM EDT - 2 years ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

CVX PUMP

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 22, 2023, 4:01 PM EDT - 2 years ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 31, 2023, 8:00 AM EDT - 2 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Erasca Further Strengthens Business Leadership with Two Key Promotions

May 16, 2023, 8:00 AM EDT - 2 years ago

Erasca Further Strengthens Business Leadership with Two Key Promotions

Erasca Reports First Quarter 2023 Financial Results and Business Updates

May 15, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2023 Financial Results and Business Updates

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

May 2, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

May 1, 2023, 8:00 AM EDT - 2 years ago

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Apr 18, 2023, 9:00 AM EDT - 2 years ago

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

JarvisFlow
JarvisFlow Nov. 14 at 2:19 PM
Guggenheim has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 3 → 5.
0 · Reply
Investor6
Investor6 Nov. 13 at 2:27 PM
$ERAS Erasca press release (ERAS): Q3 GAAP EPS of -$0.11 in-line. Cash, cash equivalents, and marketable securities were $362.4 million as of September 30, 2025, compared to $440.5 million as of December 31, 2024. Erasca expects its cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2028.
0 · Reply
RunnerSignals
RunnerSignals Nov. 12 at 9:23 PM
Market Warriors on the Move! $CNTA $TRX.X $ERAS $RANI $CHGG started down but closed strong
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Oct. 16 at 7:15 PM
$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS
2 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:44 PM
Stifel has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 4.
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 1:14 PM
Stifel initiates $ERAS coverage with Buy rating and $4.X target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition. https://notreload.xyz/erasca-gets-buy-rating-cancer-drug-potential/
0 · Reply
Quantumup
Quantumup Oct. 15 at 8:29 PM
Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.
0 · Reply
QuantInsider
QuantInsider Oct. 12 at 11:16 AM
What’s going on with $ERAS? Saw a big 7,072-contract ask-side sweep in those Jan 16 26 $2 calls on Oct 8 That’s about $842K at 172% IV Huge volume spike But with Morgan Stanley and BofA downgrades pushing it to a 2025 low, the risk is real Feels like early accumulation But I’m holding off Need to see if open interest grows next session and the call bid holds before thinking long Don’t jump the gun unless there’s follow-through in call OI and volume
0 · Reply
itoprag
itoprag Oct. 8 at 9:38 PM
$ERAS 15k shares, in at $1.29 on May 29, out today at $2.71. Not too shabby.
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 8 at 2:20 PM
👀 $ERAS Update 👀 Contracts are pushing close to 50% gains 💰
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 7 at 7:18 PM
🔥 $ERAS Jan '26 $2 Calls seeing MASSIVE flow! 📊 Flow Breakdown: Volume: 21,629 contracts Open Interest: 1,157 Avg Premium: $0.84 Total Premium: $1.8M+ 19X volume vs OI ratio! 19% ITM (in the money) That's significant premium flooding into these contracts. Volume nearly 19x open interest—someone's building a serious position or institutions rotating in. Worth watching closely! 👀
0 · Reply
kar3en_macias
kar3en_macias Oct. 3 at 7:25 PM
$ERAS BRO NXXT PRINTS NONSTOP… THIS ISN’T NORMAL 📊
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 3 at 4:38 PM
$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN
0 · Reply
Christyatmond
Christyatmond Oct. 3 at 2:43 PM
$ERAS wow a china drug is pumping hard by Logos.
1 · Reply
makedatbread88
makedatbread88 Oct. 3 at 2:40 PM
$ERAS I guess everything and anything just goes up nowadays another pretty much 100% runner ***Follow me for more winning calls!***
0 · Reply
Chad_Thunderstock
Chad_Thunderstock Oct. 3 at 8:07 AM
$ERAS 25% runup. Take your exits and don't greedy.
0 · Reply
Whiskey1679
Whiskey1679 Sep. 30 at 8:12 PM
Whiskey's Penny Picks out tomorrow 6:15 am PDT!! See my Pinned Post for 🏆 Winners 🏆!!! AH Gainers: $CJET $JELD $ERAS $NVNI $BENF
0 · Reply
DaBullRunner
DaBullRunner Sep. 30 at 8:03 PM
$ERAS there it goes… ICU is going to make a big run soon 🚨🚨🚨🚨🚨 Here’s why👇
0 · Reply
makedatbread88
makedatbread88 Sep. 30 at 5:39 PM
$ERAS breaking out here ***Follow me for more winning calls!***
1 · Reply
_www_larval_com_
_www_larval_com_ Sep. 30 at 4:27 PM
$ERAS just jumped 6% higher to 7% (~2Mv) a few minutes ago, 10/17 options, follow for more volatility.
0 · Reply
Doozio
Doozio Sep. 27 at 3:57 PM
$ERAS let’s bang bro. It’s 🐒🍌🧠⏰♾️
0 · Reply
Chucky91
Chucky91 Sep. 26 at 10:51 PM
$ERAS is a breakout growth story, combining disruptive innovation, strong execution, and accelerating momentum. With powerful market tailwinds and rising investor interest, the stock is perfectly positioned for significant upside.
0 · Reply